Physician profile
Aravind Sugumar
NPI 1124222716
$4,040.09
in general payments reported to CMS, 2019-2025
19 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2021: $242 · 2022: $440 · 2023: $1,204 · 2024: $108 · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,760 · Food and Beverage: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,760.49 |
| Food and Beverage | $1,464.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apollo Endosurgery US INC | $1,243.62 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Boston Scientific Corporation | $1,160.90 | 2019-2025 | Axios, General - Biliary Devices, Orise |
| Erbe USA INC | $537.00 | 2025 | Vio3 Erbe Jet, Hkandjetandvio3 |
| Olympus America INC. | $197.40 | 2023-2025 | Visiglide, Single Use Repositionable Clip, Evis Exera III Colonovideoscope |
| Phathom Pharmaceuticals, INC. | $148.76 | 2025 | Voquezna |
| Abbvie INC. | $145.29 | 2021-2025 | Duopa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.32 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.27 | 2022-2025 | Eohilia |
| Ipsen Biopharmaceuticals, INC | $70.86 | 2025 | Iqirvo |
| Ardelyx, INC. | $54.92 | 2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $44.81 | 2021 | |
| Qol Medical, LLC | $44.30 | 2025 | Sucraid |
| Janssen Biotech, INC. | $42.49 | 2025 | Tremfya |
| Lilly USA, LLC | $39.83 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $35.09 | 2025 | Rezdiffra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $22.37 | 2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $20.72 | 2023 | Rebyota |
| Shionogi INC | $18.84 | 2019 | |
| Pfizer INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aravind Sugumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.